Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain

Exclusion Criteria

• •Pregnancy (βHCG+ blood) or breastfeeding,
• •Neuropathic pain due to spinal cord or brain injury, phantom limb pain or algohallucinosis,
• •Fibromyalgia or algodystrophy,
• •Chronic pain syndrome that the patient cannot distinguish and/or is more intense than peripheral neuropathic pain,
• •Significant abnormalities in liver (transaminases \> 3N, cholestasis) and renal (MDRD \< 60 mL/min) tests,
• •Ongoing comorbidities: cancer, neurodegenerative pathology
• •Severe depressive disorder in progress (as determined by the clinician), history of suicide attempts or hospitalization for depression,
• •Diabetic patients (contraindicated due to the high sugar concentration of ethosuximide, 3g / 5 ml),
• •Patients who have previously received ethosuximide (epilepsy or clinical trial),
• •Surgery planned throughout the entire trial,
• •Medical and surgical history incompatible with the study,
• •Dependence on alcohol and/or drugs (for compliance purposes),
• •Known allergy to succinimides (ethosuximide, methsuximide, phensuximide),
• •Psychotic disorders,
• •Epileptic patients,
• •Patients benefiting from a legal protection measure (curatorship, guardianship, deprived of liberty or subject to judicial safeguard).